van Esser S, Veldhuis W B, van Hillegersberg R, van Diest P J, Stapper G, ElOuamari M, Borel Rinkes I H M, Mali W P Th M, van den Bosch M A A J
Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands.
Cancer Imaging. 2007 May 15;7(1):63-8. doi: 10.1102/1470-7330.2007.0012.
Our aim was to assess the feasibility and accuracy of contrast-enhanced ultrasound (CEUS) of the breast with SonoVue microbubbles for pre-operative size measurement of invasive breast carcinomas. Seven patients diagnosed with nine invasive breast carcinomas prospectively underwent gray-scale ultrasound and CEUS of the breast according to a standardized protocol. CEUS of the breast was performed by a Philips iU22 scanner equipped with a 4-8 MHz linear array transducer. We used a single dose of 2.4 ml SonoVue as contrast agent. Breast lesion morphology was scored according to the sonographic BI-RADS lexicon criteria and classified accordingly. The greatest tumor dimensions on gray-scale ultrasound and CEUS of the breast were finally compared with the greatest histopathologic tumor sizes. Gray-scale ultrasound underestimated the histopathologic tumor size in 6/9 cases (67%), whereas CEUS of the breast underestimated tumor size in only 3/9 (33%) cases. CEUS of the breast was significantly more accurate for tumor size assessment. Greatest tumor dimension as measured with gray-scale ultrasound of the breast was within 2 mm of the pathologic tumor size in only 2/9 cases (22%), whereas CEUS of the breast accurately assessed tumor size within 2 mm of pathologic tumor size in 6/9 (67%) of the cases (P<0.05). CEUS of the breast proved to be a feasible and safe procedure. It is more accurate than gray-scale ultrasound of the breast for pre-operative size assessment of invasive ductal breast carcinomas.
我们的目的是评估使用声诺维微泡进行乳腺超声造影(CEUS)在术前测量浸润性乳腺癌大小的可行性和准确性。7例被诊断为9例浸润性乳腺癌的患者根据标准化方案前瞻性地接受了乳腺灰阶超声和CEUS检查。乳腺CEUS检查使用配备4-8MHz线性阵列探头的飞利浦iU22扫描仪进行。我们使用单剂量2.4ml声诺维作为造影剂。根据超声BI-RADS词典标准对乳腺病变形态进行评分并相应分类。最后将乳腺灰阶超声和CEUS上测得的最大肿瘤尺寸与最大组织病理学肿瘤尺寸进行比较。乳腺灰阶超声在6/9例(67%)中低估了组织病理学肿瘤大小,而乳腺CEUS仅在3/9例(33%)中低估了肿瘤大小。乳腺CEUS在肿瘤大小评估方面明显更准确。乳腺灰阶超声测得的最大肿瘤尺寸仅在2/9例(22%)中与病理肿瘤大小相差2mm以内,而乳腺CEUS在6/9例(67%)中准确评估肿瘤大小在病理肿瘤大小的2mm以内(P<0.05)。乳腺CEUS被证明是一种可行且安全的检查方法。在术前评估浸润性导管癌大小时,它比乳腺灰阶超声更准确。